{"nct_id":"NCT05338775","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2022-05-25","start_date_type":"ACTUAL","primary_completion_date":"2025-05-22","primary_completion_date_type":"ACTUAL","completion_date":"2027-05-03","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["JNJ"]}